154 related articles for article (PubMed ID: 35767703)
21. SQLE Knockdown inhibits bladder cancer progression by regulating the PTEN/AKT/GSK3β signaling pathway through P53.
Zou F; Chen W; Song T; Xing J; Zhang Y; Chen K; Hu W; Li L; Ning J; Li C; Yu W; Cheng F
Cancer Cell Int; 2023 Sep; 23(1):221. PubMed ID: 37770925
[TBL] [Abstract][Full Text] [Related]
22. Cyclin-dependent kinase 12 deficiency reprogrammes cellular metabolism to alleviate ferroptosis potential and promote the progression of castration-resistant prostate cancer.
Zhang H; Zhou Y; Feng Y; Hou W; Chen Y; Xing Z; Zhang Y; Wei Q; Yin Y; Guo J; Hu H
Clin Transl Med; 2024 May; 14(5):e1678. PubMed ID: 38736108
[TBL] [Abstract][Full Text] [Related]
23. Anti-androgen therapy induces transcriptomic reprogramming in metastatic castration-resistant prostate cancer in a murine model.
Zhao Y; Peng X; Baldwin H; Zhang C; Liu Z; Lu X
Biochim Biophys Acta Mol Basis Dis; 2021 Jul; 1867(7):166151. PubMed ID: 33892077
[TBL] [Abstract][Full Text] [Related]
24. Squalene epoxidase promotes breast cancer progression by regulating CCNB1 protein stability.
Tuluhong D; Gao H; Li X; Wang L; Zhu Y; Xu C; Wang J; Li H; Li Q; Wang S
Exp Cell Res; 2023 Dec; 433(1):113805. PubMed ID: 37839786
[TBL] [Abstract][Full Text] [Related]
25. OSBPL2 deficiency upregulate SQLE expression increasing intracellular cholesterol and cholesteryl ester by AMPK/SP1 and SREBF2 signalling pathway.
Zhang C; Zhang H; Zhang M; Lin C; Wang H; Yao J; Wei Q; Lu Y; Chen Z; Xing G; Cao X
Exp Cell Res; 2019 Oct; 383(2):111512. PubMed ID: 31356817
[TBL] [Abstract][Full Text] [Related]
26. Identification of
Pearson HB; Li J; Meniel VS; Fennell CM; Waring P; Montgomery KG; Rebello RJ; Macpherson AA; Koushyar S; Furic L; Cullinane C; Clarkson RW; Smalley MJ; Simpson KJ; Phesse TJ; Shepherd PR; Humbert PO; Sansom OJ; Phillips WA
Cancer Discov; 2018 Jun; 8(6):764-779. PubMed ID: 29581176
[TBL] [Abstract][Full Text] [Related]
27. Negative cross talk between LIMK2 and PTEN promotes castration resistant prostate cancer pathogenesis in cells and in vivo.
Nikhil K; Kamra M; Raza A; Shah K
Cancer Lett; 2021 Feb; 498():1-18. PubMed ID: 32931887
[TBL] [Abstract][Full Text] [Related]
28. Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer.
Hao J; Ci X; Xue H; Wu R; Dong X; Choi SYC; He H; Wang Y; Zhang F; Qu S; Zhang F; Haegert AM; Gout PW; Zoubeidi A; Collins C; Gleave ME; Lin D; Wang Y
Eur Urol; 2018 Jun; 73(6):949-960. PubMed ID: 29544736
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of Pten deficient Castration Resistant Prostate Cancer by Targeting of the SET - PP2A Signaling axis.
Hu X; Garcia C; Fazli L; Gleave M; Vitek MP; Jansen M; Christensen D; Mulholland DJ
Sci Rep; 2015 Nov; 5():15182. PubMed ID: 26563471
[TBL] [Abstract][Full Text] [Related]
30. A chemical biology screen identifies a vulnerability of neuroendocrine cancer cells to SQLE inhibition.
Mahoney CE; Pirman D; Chubukov V; Sleger T; Hayes S; Fan ZP; Allen EL; Chen Y; Huang L; Liu M; Zhang Y; McDonald G; Narayanaswamy R; Choe S; Chen Y; Gross S; Cianchetta G; Padyana AK; Murray S; Liu W; Marks KM; Murtie J; Dorsch M; Jin S; Nagaraja N; Biller SA; Roddy T; Popovici-Muller J; Smolen GA
Nat Commun; 2019 Jan; 10(1):96. PubMed ID: 30626880
[TBL] [Abstract][Full Text] [Related]
31. Structure and inhibition mechanism of the catalytic domain of human squalene epoxidase.
Padyana AK; Gross S; Jin L; Cianchetta G; Narayanaswamy R; Wang F; Wang R; Fang C; Lv X; Biller SA; Dang L; Mahoney CE; Nagaraja N; Pirman D; Sui Z; Popovici-Muller J; Smolen GA
Nat Commun; 2019 Jan; 10(1):97. PubMed ID: 30626872
[TBL] [Abstract][Full Text] [Related]
32. p53 status in the primary tumor predicts efficacy of subsequent abiraterone and enzalutamide in castration-resistant prostate cancer.
Maughan BL; Guedes LB; Boucher K; Rajoria G; Liu Z; Klimek S; Zoino R; Antonarakis ES; Lotan TL
Prostate Cancer Prostatic Dis; 2018 Jun; 21(2):260-268. PubMed ID: 29302046
[TBL] [Abstract][Full Text] [Related]
33. SQLE Mediates Metabolic Reprogramming to Promote LN Metastasis in Castration-Resistant Prostate Cancer.
Xu Z; Huang L; Dai T; Pei X; Xia L; Zeng G; Ye M; Liu K; Zeng F; Han W; Jiang S
Onco Targets Ther; 2021; 14():4285-4295. PubMed ID: 34335030
[TBL] [Abstract][Full Text] [Related]
34. Upregulation of SQLE Contributes to Poor Survival in Head and Neck Squamous Cell Carcinoma.
Li J; Yang T; Wang Q; Li Y; Wu H; Zhang M; Qi H; Zhang H; Li J
Int J Biol Sci; 2022; 18(9):3576-3591. PubMed ID: 35813482
[TBL] [Abstract][Full Text] [Related]
35. Age-related cholesterol and colorectal cancer progression: Validating squalene epoxidase for high-risk cases.
Jun SY; Yoon HR; Yoon JY; Lee JJ; Kim JY; Kim JM; Kim NS
Aging Cell; 2024 Mar; ():e14152. PubMed ID: 38517197
[TBL] [Abstract][Full Text] [Related]
36. Targeting prosurvival BCL2 signaling through Akt blockade sensitizes castration-resistant prostate cancer cells to enzalutamide.
Pilling AB; Hwang C
Prostate; 2019 Aug; 79(11):1347-1359. PubMed ID: 31228231
[TBL] [Abstract][Full Text] [Related]
37. Squalene epoxidase is a bona fide oncogene by amplification with clinical relevance in breast cancer.
Brown DN; Caffa I; Cirmena G; Piras D; Garuti A; Gallo M; Alberti S; Nencioni A; Ballestrero A; Zoppoli G
Sci Rep; 2016 Jan; 6():19435. PubMed ID: 26777065
[TBL] [Abstract][Full Text] [Related]
38. Squalene Epoxidase: Its Regulations and Links with Cancers.
Zhang L; Cao Z; Hong Y; He H; Chen L; Yu Z; Gao Y
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612682
[TBL] [Abstract][Full Text] [Related]
39. SQLE, A Key Enzyme in Cholesterol Metabolism, Correlates With Tumor Immune Infiltration and Immunotherapy Outcome of Pancreatic Adenocarcinoma.
You W; Ke J; Chen Y; Cai Z; Huang ZP; Hu P; Wu X
Front Immunol; 2022; 13():864244. PubMed ID: 35720314
[TBL] [Abstract][Full Text] [Related]
40. Reversal of Lactate and PD-1-mediated Macrophage Immunosuppression Controls Growth of PTEN/p53-deficient Prostate Cancer.
Chaudagar K; Hieromnimon HM; Khurana R; Labadie B; Hirz T; Mei S; Hasan R; Shafran J; Kelley A; Apostolov E; Al-Eryani G; Harvey K; Rameshbabu S; Loyd M; Bynoe K; Drovetsky C; Solanki A; Markiewicz E; Zamora M; Fan X; Schürer S; Swarbrick A; Sykes DB; Patnaik A
Clin Cancer Res; 2023 May; 29(10):1952-1968. PubMed ID: 36862086
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
